The Emerging Role of Homologous Recombination Deficiency Testing and the Progress of PARP Inhibitors in Advanced Ovarian Cancer: Interviews with Three Key Opinion Leaders
Ovarian cancer is the most lethal gynaecologic malignancy worldwide because of its vague presentation, insidious nature, recurrence, and drug resistance.